Pharmacological properties of new neuroleptic compounds.
RMI 61 140, RMI 61 144 and RMI 61 280 are newly synthetized N-[8-R-dibenzo(b,f)oxepin-10-yl]-N'-methyl-piperazine-maleates which show interesting psychopharmacologic effects. This work contains the results of a study performed with these three compounds, in order to demonstrate their neuropsycholeptic activity in comparison with chloropromazine (CPZ) and chlordiazepoxide (CPD). The inhibition of motility observed in mice shows that the compounds reduce the normal spontaneous motility as well as the muscle tone. The central-depressant activity is evidenced by increased barbiturate-induced sleep and a remarkable eyelid ptosis can also be observed. Our compounds do not show any activity on electroshock just as do CPZ and CPD. As to the antipsychotic outline, our compounds show strong reduction of lethality due to amphetamine in grouped mice and a strong antiapomorphine activity. They show also an antiaggressive effect and an inhibitory activity on avoidance behaviour much stronger than CPZ. We have also found extrapyramidal effects, as catalepsy, common to many tranquillizers of the kind of the standards used by us. As for vegetative phenomena, the compounds show hypotensive dose related action ranging from moderate to strong, probably due to an a-receptor inhibition. Adrenolytic activity against lethal doses of adrenaline, antiserotonin and antihistaminic effects, as well as other actions (hypothermia, analgesia, etc.) confirm that RMI 61 140, RMI 61 144 and RMI 61 280 are endowed with pharmacologic properties similar and more potent than those of CPZ. Studies on the metabolism of brain catecholamines show that they are similar to CPZ, although with less effect on dopamine level.
D000374:Aggression / Q000187:drug effects; D000661:Amphetamine / Q000037:antagonists & inhibitors; D000818:Animals; D001058:Apomorphine / Q000037:antagonists & inhibitors; D001362:Avoidance Learning / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects*; D001794:Blood Pressure / Q000187:drug effects; D002707:Chlordiazepoxide / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D003990:Dibenzoxepins / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D004837:Epinephrine / Q000037:antagonists & inhibitors; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists; D006801:Humans; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009119:Muscle Contraction / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology*; D051381:Rats; D012890:Sleep / Q000187:drug effects; D013997:Time Factors; D014149:Tranquilizing Agents / Q000494:pharmacology*
D003990:Dibenzoxepins; D006634:Histamine H1 Antagonists; D010879:Piperazines; D014149:Tranquilizing Agents; D002707:Chlordiazepoxide; D000661:Amphetamine; D001058:Apomorphine; D002746:Chlorpromazine; D004837:Epinephrine